Stay updated on Durvalumab & Tremelimumab in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Durvalumab & Tremelimumab in NSCLC Clinical Trial page.

Latest updates to the Durvalumab & Tremelimumab in NSCLC Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedNapoli, Italy, 80131 was replaced with Naples, Italy, 80131 in the study locations.SummaryDifference0.0%

- Check18 days agoChange DetectedRevision metadata updated: added Revision: v3.5.0 and removed Revision: v3.4.3. No study details or participant information are affected.SummaryDifference0.0%

- Check25 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3. This is a minor technical update with no changes to study content or functionality.SummaryDifference0.0%

- Check54 days agoChange DetectedRevision: v3.4.2 was added and Revision: v3.4.1 was removed. This is a minor version/metadata update that does not affect the study content or the page’s primary functions.SummaryDifference0.0%

- Check61 days agoChange DetectedThe page now displays Revision: v3.4.1 and removed Revision: v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check68 days agoChange DetectedThe page now includes a glossary toggle and a visible QC status field ('Last Update Submitted that Met QC Criteria'). The previous QC wording was removed/adjusted and versioning text was updated.SummaryDifference0.1%

Stay in the know with updates to Durvalumab & Tremelimumab in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Durvalumab & Tremelimumab in NSCLC Clinical Trial page.